1. Moojecin: The first disintegrin from Bothrops moojeni venom and its antitumor activity in acute myeloid leukemia.
- Author
-
Almeida GO, Cintra ACO, Silva TA, de Oliveira IS, Correia LIV, Torquato RJS, Ferreira Junior RS, Arantes EC, and Sampaio SV
- Subjects
- Humans, Animals, HL-60 Cells, Crotalid Venoms chemistry, Platelet Aggregation drug effects, Cell Proliferation drug effects, Cell Movement drug effects, Cell Line, Tumor, Venomous Snakes, Bothrops, Disintegrins pharmacology, Disintegrins chemistry, Disintegrins isolation & purification, Leukemia, Myeloid, Acute drug therapy, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Antineoplastic Agents isolation & purification
- Abstract
Disintegrins are a class of peptides found in snake venom that inhibit the activity of integrins, which are essential cell adhesion receptors in tumor progression and development. In this work, moojecin, a RGD disintegrin, was isolated from Bothrops moojeni snake venom, and its antitumor potential in acute myeloid leukemia (AML) HL-60 and THP-1 cells was characterized. The isolation was performed using a C
18 reverse-phase column in two chromatographic steps, and its molecular mass is 7417.84 Da. N-terminal and de novo sequencing was performed to identify moojecin. Moojecin did not show cytotoxic or antiproliferative activity in THP-1 and HL-60 at tested concentrations, but it exhibited significant antimigratory activity in both cell lines, as well as inhibition of angiogenesis in the tube formation assay on Matrigel in a dose-dependent manner. A stronger interaction with integrin αVβ3 was shown in integrin interaction assays compared to α5β1, and the platelet aggregation assay indicated an IC50 of 5.039 μg/mL. Preliminary evaluation of disintegrin toxicity revealed no incidence of hemolysis or cytotoxic effects on peripheral blood mononuclear cells (PBMCs) across the tested concentrations. Thus, this is the first study to report the isolation, functional and structural characterization of a disintegrin from B. moojeni venom and bring a new perspective to assist in AML treatment., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier B.V.)- Published
- 2024
- Full Text
- View/download PDF